CL2020002246A1 - Expresión de proteína de superficie a neumocócica (pspa) - Google Patents

Expresión de proteína de superficie a neumocócica (pspa)

Info

Publication number
CL2020002246A1
CL2020002246A1 CL2020002246A CL2020002246A CL2020002246A1 CL 2020002246 A1 CL2020002246 A1 CL 2020002246A1 CL 2020002246 A CL2020002246 A CL 2020002246A CL 2020002246 A CL2020002246 A CL 2020002246A CL 2020002246 A1 CL2020002246 A1 CL 2020002246A1
Authority
CL
Chile
Prior art keywords
pspa
surface protein
pneumococcal surface
protein expression
expression
Prior art date
Application number
CL2020002246A
Other languages
English (en)
Inventor
Rajan Sriraman
Ramesh Venkat Matur
Narender Dev Mantena
Mahima Datla
Swetha Kamireddy
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CL2020002246A1 publication Critical patent/CL2020002246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la expresión de proteína de superficie A neumocócica (PspA). La invención representa un avance en el campo de ingeniería genética y tecnología de vacunas. La invención describe vectores de expresión y células hospederas recombinantes para la expresión del péptido PspA truncado. La invención también describe composiciones de vacuna que comprenden los péptidos truncados como proteína portadora.
CL2020002246A 2018-03-01 2020-08-31 Expresión de proteína de superficie a neumocócica (pspa) CL2020002246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01

Publications (1)

Publication Number Publication Date
CL2020002246A1 true CL2020002246A1 (es) 2021-01-15

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002246A CL2020002246A1 (es) 2018-03-01 2020-08-31 Expresión de proteína de superficie a neumocócica (pspa)

Country Status (20)

Country Link
US (2) US11725029B2 (es)
EP (1) EP3758746A1 (es)
JP (2) JP7334176B2 (es)
KR (1) KR102774793B1 (es)
CN (1) CN112118865B (es)
AU (1) AU2019226487B2 (es)
BR (1) BR112020017431A2 (es)
CA (1) CA3091583A1 (es)
CL (1) CL2020002246A1 (es)
CU (1) CU24709B1 (es)
EA (1) EA202092065A1 (es)
IL (1) IL277023B2 (es)
MX (1) MX2020009049A (es)
MY (1) MY204760A (es)
PH (1) PH12020551357A1 (es)
SA (1) SA520420041B1 (es)
SG (1) SG11202008124XA (es)
UA (1) UA129585C2 (es)
WO (1) WO2019167008A1 (es)
ZA (1) ZA202005414B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
JP4712716B2 (ja) * 2004-09-09 2011-06-29 財団法人地球環境産業技術研究機構 プロモーター機能を有するｄｎａ断片
CN105483067A (zh) 2008-06-25 2016-04-13 瓦克星治疗有限责任公司 可调型基因自杀机制组合物和方法
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
CN112118865B (zh) 2025-03-28
JP2023154063A (ja) 2023-10-18
SG11202008124XA (en) 2020-09-29
US20230322871A1 (en) 2023-10-12
AU2019226487A1 (en) 2020-09-10
US20210009641A1 (en) 2021-01-14
IL277023B1 (en) 2025-07-01
MY204760A (en) 2024-09-11
MX2020009049A (es) 2020-10-12
UA129585C2 (uk) 2025-06-11
JP2021516050A (ja) 2021-07-01
CA3091583A1 (en) 2019-09-06
JP7645946B2 (ja) 2025-03-14
JP7334176B2 (ja) 2023-08-28
CU20200064A7 (es) 2021-04-07
PH12020551357A1 (en) 2021-08-23
IL277023A (en) 2020-10-29
EP3758746A1 (en) 2021-01-06
EA202092065A1 (ru) 2020-11-19
ZA202005414B (en) 2022-02-23
KR20200129121A (ko) 2020-11-17
BR112020017431A2 (pt) 2021-01-19
SA520420041B1 (ar) 2024-03-14
IL277023B2 (en) 2025-11-01
AU2019226487B2 (en) 2025-08-07
WO2019167008A1 (en) 2019-09-06
CU24709B1 (es) 2024-06-11
KR102774793B1 (ko) 2025-02-27
US11725029B2 (en) 2023-08-15
CN112118865A (zh) 2020-12-22

Similar Documents

Publication Publication Date Title
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
BR112017014560A2 (pt) profármacos de cnp
MX2022015081A (es) Variantes de hsd17b13 y usos de las mismas.
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
MX2024015050A (es) L-asparaginasa modificada
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
CO2018009120A2 (es) Genes del factor viii optimizados
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
MX2024007348A (es) Casetes de expresion optimizados del gen del factor de coagulacion ix humano y su uso.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
UY40420A (es) Formulación que comprende una superóxido dismutasa
UY37970A (es) Plataforma de presentación, productos y métodos con endosporas basadas en paenibacillus
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
MX2020010718A (es) Composiciones y metodos para el trasplante de celulas madre.
MX2018000845A (es) Vector vírico orf recombinante.
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
PY1996572A (es) Plataformas, productos y métodos para la expresión en endosporas
CO2018001339A2 (es) Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados
MX2018003445A (es) Expresion de proteinas que contienen fc.
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков